Agreement - January 20, 2025
Orexo converts future rights for OX-MPI to shares in Gesynta
Orexo has announced that rights to future transaction proceeds and royalty on future net revenues for the drug candidate vipoglanstat (OX-MPI), have been converted to shares in Gesynta Pharma.
Financing - January 20, 2025
Gesynta Pharma raises SEK 304 million
Gesynta Pharma has secured SEK 304 million in a Series B financing round led by Innovestor Life Science.
Collaboration - January 16, 2025
New Nordic consortia on post-COVID condition
NordForsk has decided to fund three Nordic networking activities to support knowledge development on the post-COVID condition (PCC).
Science article - January 16, 2025
New research shows that AI can improve ovarian cancer diagnoses
A new international study led by researchers at Karolinska Institutet shows that AI-based models can outperform human experts at identifying ovarian cancer in ultrasound images.
Acquisition - January 15, 2025
GSK to acquire IDRx for up to USD 1.15 billion
IDRx is a Boston-based, clinical-stage biopharmaceutical company dedicated to developing precision therapeutics for the treatment of GIST.
Financing - January 15, 2025
Rappta Therapeutics in agreement with SpringWorks Therapeutics
Rappta Therapeutics has announced an exclusive global license agreement with SpringWorks Therapeutics for RPT04402, a first-in-class molecular glue of specific Protein Phosphatase 2A (PP2A) complexes.
